Claims for Patent: 10,182,561

Summary for Patent: 10,182,561

Title:	Method of using a transgenic chicken to produce exogenous proteins in its eggs
Abstract:	A transgenic avian containing in its genome an exogenous nucleotide sequence which includes a promoter component and a vector with reduced promoter interference wherein the exogenous nucleotide sequence is integrated into the genome and the avian.
Inventor(s):	Harvey; Alex J. (Athens, GA), Rapp; Jeffrey C. (Athens, GA)
Assignee:	ALEXION PHARMACEUTICALS, INC. (New Haven, CT)
Application Number:	15/181,987
Patent Claims:	1. A method of using a transgenic chicken to produce an exogenous protein comprising: providing a transgenic chicken whose genome comprises a self-inactivating avian leukosis viral (ALV) vector encoding an exogenous protein operably linked to a promoter; obtaining a hard shell egg containing the exogenous protein from the transgenic chicken, wherein the promoter comprises a nucleic acid sequence that is at least 90% identical to a nucleic acid molecule comprising from 5' to 3': i) an ovalbumin Dnase hypersensitive site (DNS) III consisting of nucleotides 3253-3559 of SEQ ID NO: 22; ii) an ovalbumin DNS II consisting of nucleotides 5629-6009 of SEQ ID NO: 22; iii) an ovalbumin DNS I consisting of nucleotides 6359-6659 of SEQ ID NO: 22; iv) a 5' UTR-5' portion from Exon L consisting of nucleotides 6659-6705 of SEQ ID NO: 22; v) intron A consisting of nucleotides 6706-8294 of SEQ ID NO: 22; vi) a 5' UTR-3' portion from Exon I consisting of nucleotides 8295-8311 of SEQ ID NO: 22; vii) a 3' UTR. 2. The method of claim 1, wherein the exogenous protein is a human protein. 3. The method of claim 1, wherein the exogenous protein is a therapeutic protein. 4. The method of claim 1 wherein the exogenous protein is selected from the group consisting of erythropoietin, GM-C SF, interferon, fusion protein, CTLA4-Fc fusion protein, growth hormones, cytokines, structural, interferon, lysozyme, .beta.-casein, albumin, .alpha.-1 antitrypsin, antithrombin III, collagen, factors VIII, IX, X (and the like), fibrinogen, lactoferrin, protein C, tissue-type plasminogen activator (tPA), somatotropin, chymotrypsin, immunoglobulins, antibodies, immunotoxins, factor VIII, b-domain deleted factor VIII, factor VIIa, factor IX, anticoagulants; hirudin, alteplase, reteplase, tPA- 3 of 5 domains deleted, insulin, insulin lispro, insulin aspart, insulin glargine, long-acting insulin analogs, glucagons, thyroid-stimulating hormone (tsh), follitropin-beta, follicle-stimulating hormone (fsh), pdgh, inf-beta, inf-alpha 1, ifn-alpha 2, inf-beta, inf-beta 1b, ifn-beta 1a, ifn-gamma, ifn-gamma 1b, il-2, il-11, HBsAg, dornase-alpha dnase, beta glucocerebrosidase, tnf-alpha, il-2-diptheria toxin fusion protein, tnfr-lgg fragment fusion protein laronidase, DNAses, alefacept, tositumomab, murine mab, alemtuzumab, rasburicase, agalsidase beta, teriparatide, parathyroid hormone derivatives, adalimumab (lgg1), anakinra, biological modifier, nesiritide, human b-type natriuretic peptide (hbnp), colony stimulating factors, pegvisomant, human growth hormone receptor antagonist, recombinant activated protein c, omalizumab, immunoglobulin E blocker, lbritumomab tiuxetan, ACTH, glucagon, somatostatin, somatotropin, thymosin, parathyroid hormone, pigmentary hormones, somatomedin, luteinizing hormone, chorionic gonadotropin, hypothalmic releasing factors, etanercept, antidiuretic hormones, prolactin, thyroid stimulating hormone, human immunoglobulin polypeptide D region, human immunoglobulin polypeptide J region, human immunoglobulin polypeptide C region, human immunoglobulin light chain, human immunoglobulin heavy chain, an human immunoglobulin heavy chain variable region, and an immunoglobulin light chain variable region. 5. The method of claim 1 further comprising isolating said protein.

Details for Patent 10,182,561

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974		2024-12-29
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984		2024-12-29
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985		2024-12-29
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990		2024-12-29
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974		2024-12-29
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	March 05, 1973		2024-12-29